Ovid Therapeutics Inc. (NASDAQ: OVID) reported Q4 EPS of $0.00, $0.22 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $140 thousand versus the consensus estimate of $8.62 million.

For earnings history and earnings-related data on Ovid Therapeutics Inc. (OVID) click here.